Decreased suicide rates in recent antidepressant clinical trials

Abstract

RationaleThe last systematic analysis of suicidality in antidepressant clinical trials submitted for approval by the US Food and Drug Administration was in 2000. Given the attention to suicide and antidepressants in the early 2000s, the authors aimed to evaluate if there have been any changes in suicide rates in antidepressant clinical trials following 2000.Objective and MethodsThe Integrated Safety Summary data from approval packets for 14 investigational antidepressant programs (1991–2013, 40,857 patients, 10,890.5 exposure years) were used to calculate suicides and suicide attempts per 100,000 patient exposure years (standardized rates) for antidepressant and placebo treatment groups separately. Suicides/suicide attempt rates, mean age, and percent female were compared between 1991 and 1998 (pre-2000) and 2002–2013 (post-2000). Drug-placebo differences in suicide/suicide attempt rates were explored.ResultsAmong antidepressant-treated patients, the standardized suicide rate decreased significantly from pre- to post-2000 (643.6 to 25.8, p < 0.0001) as did the standardized suicide attempt rate (3975.7 to 645.4, p < 0.0001). For placebo-treated patients, the decrease was not significant for suicide rate (471.1 to 174.2, p = 0.66) but was significant for suicide attempt rate (from 3538.3 to 522.6, p < 0.001). Regression analysis showed a similar pattern with suicide/suicide attempt rates decreasing over time. None of the drug-placebo comparisons in suicide or suicide attempt rates were statistically significant. There was no change in percent female or mean age of patients in trials pre- and post-2000.ConclusionsDeaths by suicide and suicide attempts have decreased significantly in antidepressant clinical trials following 2000 compared to the decade before 2000. Basic demographic features of the patients have remained consistent and medication treatment effects on suicidality were not apparent. These findings may reflect enhanced screening procedures and effective exclusion of suicidal patients in clinical trials for depression.

Suicide in Northern Ireland: epidemiology, risk factors, and prevention

“…There is debate about the effectiveness of antidepressants in suicide prevention 76,77,78 . In a data linkage study covering 1989-1999 inclusive, Kelly and colleagues found that for adults aged 30 years and above, there was an inverse relationship between antidepressant prescribing and suicide 79 .…”

Relationship between suicide rate and antidepressant prescription: An ecological study in the People's Republic of China

“…Many ecological studies including this study found that antidepressants have protective effects on suicidality (Nischal, Tripathi, Nischal, & Trivedi, 2012). A recent cohort study and randomized control trials advocate about the positive effects of antidepressants in the protection of suicides (Cheung et al, 2015; Khan, Fahl Mar, Gokul, & Brown, 2018). As shown by the previous study the suicidality might increase during the initial phase of treatment with antidepressants.…”

Mortality during US FDA clinical trials in patients with diabetes, hypertension, depression and schizophrenia

“…Therefore, these data suggest that the 'healthiest' of the population of depression and schizophrenic patients still died at higher rates than the 'healthiest' of the population of diabetes and hypertension patients in clinical trials. This is even more striking if one considers that suicidality, which is known to be associated with psychiatric illnesses, is systematically screened out of clinical trials such that potential patients who appear to be at higher risk of suicidal behaviour during the trial are excluded from participation (Khan et al 2018).…”